Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 7, 2009, Pages 1258-1264

  Takatsu, Noritaka ^a   Matsui, Toshiyuki ^a   Murakami, Yuji ^a   Ishihara, Hiroshi ^a   Hisabe, Takashi ^a   Nagahama, Takashi ^a   Maki, Shinichirou ^a   Beppu, Takahiro ^a   Takaki, Yasuhiro ^a   Hirai, Fumihito ^a   Yao, Kenshi ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Adverse reactions; Azathioprine; Inflammatory bowel disease; Thiopurine S methyltransferase

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; AZATHIOPRINE; BIOLOGICAL MARKER; INFLIXIMAB; MESALAZINE; NUCLEOTIDE DERIVATIVE; PREDNISOLONE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ALLELE; ALOPECIA; ARTHRALGIA; ARTICLE; BEHCET DISEASE; BLOOD LEVEL; CROHN DISEASE; DIARRHEA; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERITIS; ENZYME POLYMORPHISM; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE SEQUENCE; GENOTYPE; HEADACHE; HUMAN; JAPANESE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MARKER GENE; MUTANT; MUTATION RATE; MYALGIA; NAUSEA; PHARMACOGENETICS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; TUBERCULOSIS; ULCERATIVE COLITIS; VOMITING; WILD TYPE;

EID: 68749111832     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05917.x     Document Type: Article

References (30)

1. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 1962 49 : 592 3.
2. Rhodes J, Bainton D, Beck P et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971 2 : 1273 6.
3. Willoughby JMT, Kumar PJ, Beckett J et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971 2 : 944 7.
4. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N. Engl. J. Med. 1980 302 : 981 7.
5. Jewel DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br. Med. J. 1974 4 : 627 30.
6. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. J. 1982 284 : 1291 2.
7. Marinaki AM, Ansari A, Duley JA et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004 14 : 181 7.
8. Derijks LJ, Gilissen LP, Hooymans PM et al. Review article: thiopurines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006 24 : 715 29.
9. Schwab M, Schaffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002 12 : 429 36.
10. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 13.
11. Colombel JF, Ferrari N, Debuysere H et al. Genotype analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 : 1025 30.
12. Lichtenstein GR, Abreu MT, Cohen R et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 935 9.
13. Hibi T, Naganuma M, Kitahora T et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 2003 38 : 740 6.
14. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980 32 : 651 62.
15. Srikumar S, Danny H, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 2008 64 : 753 67.
16. Kumagai K, Hiyama K, Ishioka S et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001 11 : 275 8.
17. Kubota T, Nishida A, Takeuchi K et al. Frequency distribution of thioprine S-methyltransferase activity in red blood cells of a healthy Japanese population. Ther. Drug Monit. 2004 26 : 319 21.
18. Hiratsuka M, Inoue T, Omori F et al. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat. Res. 2000 449 : 91 5.
19. Herrlinger KR, Jewell DP. Interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2006 24 : 1403 12.
20. Winter JW, Gaffney D, Shapiro D et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2007 25 : 1069 77.
21. Sayani FA, Prosser C, Bailey RJ et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 2005 19 : 147 51.
22. Cuffari C, Theoret Y, Latour S et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996 39 : 401 6.
23. Cuffari C, Dassopoulos T, Turnbough L et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2004 2 : 410 17.
24. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 13.
25. Wright S, Sanders DS, Lobo AJ et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004 53 : 1123 8.
26. Osterman MT, Kundu R, Lichtenstein GR et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006 130 : 1047 53.
27. Belaiche J, Desager JP, Horsmans Y et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scan. J. Gastroenterol. 2001 36 : 71 6.
28. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 2004 99 : 1744 8.
29. de Boer NK, Wong DR, Jharap B et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am. J. Gastroenterol. 2007 102 : 2747 53.
30. Gilissen LP, Bierau J, Derijks LJ et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 2005 22 : 605 11.